Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall-Winter 2022-2023: A Cross-Sectional Retrospective Study.

COVID-19 SARS-CoV-2 United States hospitalization influenza

Journal

Diseases (Basel, Switzerland)
ISSN: 2079-9721
Titre abrégé: Diseases
Pays: Switzerland
ID NLM: 101636232

Informations de publication

Date de publication:
03 Jan 2024
Historique:
received: 20 11 2023
revised: 25 12 2023
accepted: 28 12 2023
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 22 1 2024
Statut: epublish

Résumé

Influenza and COVID-19 contribute significantly to the infectious disease burden during the respiratory season, but their relative burden remains unknown. This study characterizes the frequency and severity of medically attended COVID-19 and influenza during the peak of the 2022-2023 influenza season in the pediatric, adult, and older adult populations and characterizes the prevalence of underlying conditions among patients hospitalized with COVID-19. This cross-sectional analysis included individuals in the Veradigm EHR Database linked to Komodo claims data with a medical encounter between 1 October 2022 and 31 March 2023 (study period). Patients with medical encounters were identified with a diagnosis of COVID-19 or influenza during the study period and stratified based on the highest level of care received with that diagnosis. Among 23,526,196 individuals, there were more COVID-19-related medical encounters than influenza-related encounters, overall and by outcome. Hospitalizations with COVID-19 were more common than hospitalizations with influenza overall (incidence ratio = 4.6) and in all age groups. Nearly all adults hospitalized with COVID-19 had at least one underlying medical condition, but 37.1% of 0-5-year-olds and 25.0% of 6-17-year-olds had no underlying medical conditions. COVID-19 was associated greater burden than influenza during the peak of the 2022-2023 influenza season.

Identifiants

pubmed: 38248367
pii: diseases12010016
doi: 10.3390/diseases12010016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Moderna Therapeutics (United States)
ID : N/A

Auteurs

Hagit Kopel (H)

Moderna, Inc., Cambridge, MA 02139, USA.

Alina Bogdanov (A)

Veradigm, Chicago, IL 60654, USA.

Christopher Adams (C)

Veradigm, Chicago, IL 60654, USA.

Isabelle H Winer (IH)

Veradigm, Chicago, IL 60654, USA.

Machaon Bonafede (M)

Veradigm, Chicago, IL 60654, USA.

Van Hung Nguyen (VH)

VHN Consulting Inc., Montreal, QC H2V 3L8, Canada.

James A Mansi (JA)

Moderna, Inc., Cambridge, MA 02139, USA.

Classifications MeSH